Besides, there is less abuse potential, fewer gastrointestinal-related complications and reduced respiratory depression for DOR and KOR agonists compared to MOR agonists (Benyamin et al., 2008; Pasternak and Pan, 2013; Imam et al., 2018). The gene discussed is OPRK1; the disease is Respiratory insufficiency due to muscle weakness.